Patents by Inventor Joseph M. Backer
Joseph M. Backer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7807778Abstract: The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety bound to the targeting moiety; the biological conjugate having a covalent bond between the thiol group of SEQ ID NO:2 and a functional group in the binding moiety. The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety that comprises an adapter protein, the adapter protein having a thiol group; the biological conjugate having a disulfide bond between the thiol group of SEQ ID NO:2 and the thiol group of the adapter protein.Type: GrantFiled: March 14, 2008Date of Patent: October 5, 2010Assignee: SibTech, Inc.Inventors: Marina V. Backer, Joseph M. Backer
-
Publication number: 20100104550Abstract: Cleavage of BIP (Immunoglobulin binding protein) by subtilase toxin and its application to inhibiting growth of or killing of cells. This has application to treatment of cancers and to conformational diseases and in particular to conformational diseases involving BiP that are influenced by cleavage by the subtilase cytotoxin. The invention also relates to subtilase toxin molecules specifically targeting proliferating cells, in particular tumor cells, or cells expressing a vascular endothelial growth factor receptor.Type: ApplicationFiled: August 3, 2007Publication date: April 29, 2010Applicants: ADELAIDE RESEARCH AND INNOVATION, SIBTECH, INC.Inventors: Adrienne Webster Paton, James Cleland Paton, Marina V. Backer, Joseph M. Backer
-
Patent number: 7700557Abstract: The present invention is directed to an isolated polypeptide including: (1) the A subunit of Shiga-like bacterial toxin, wherein said subunit has the nucleic acid sequence of SEQ ID NO:9; and (2) human vascular endothelial growth factor wherein the growth factor has the nucleic acid sequence of SEQ ID NO:10; wherein the isolated polypeptide possesses ribosome inactivating activity. The present invention is also directed to compositions for inhibiting endothelial cell growth in a patient.Type: GrantFiled: August 14, 2007Date of Patent: April 20, 2010Assignee: SibTech, Inc.Inventors: Marina V. Backer, Joseph M. Backer
-
Publication number: 20090023649Abstract: The present invention is directed to an isolated polypeptide including: (1) the A subunit of Shiga-like bacterial toxin, wherein said subunit has the nucleic acid sequence of SEQ ID NO:9; and (2) human vascular endothelial growth factor wherein the growth factor has the nucleic acid sequence of SEQ ID NO:10; wherein the isolated polypeptide possesses ribosome inactivating activity. The present invention is also directed to compositions for inhibiting endothelial cell growth in a patient.Type: ApplicationFiled: August 14, 2007Publication date: January 22, 2009Inventors: Marina V. Backer, Joseph M. Backer
-
Publication number: 20080312410Abstract: The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety bound to the targeting moiety; the biological conjugate having a covalent bond between the thiol group of SEQ ID NO:2 and a functional group in the binding moiety. The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety that comprises an adapter protein, the adapter protein having a thiol group; the biological conjugate having a disulfide bond between the thiol group of SEQ ID NO:2 and the thiol group of the adapter protein.Type: ApplicationFiled: March 14, 2008Publication date: December 18, 2008Inventors: Marina V. Backer, Joseph M. Backer
-
Patent number: 7355019Abstract: The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety bound to the targeting moiety; the biological conjugate having a covalent bond between the thiol group of SEQ ID NO:2 and a functional group in the binding moiety. The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety that comprises an adapter protein, the adapter protein having a thiol group; the biological conjugate having a disulfide bond between the thiol group of SEQ ID NO:2 and the thiol group of the adapter protein.Type: GrantFiled: March 18, 2005Date of Patent: April 8, 2008Assignee: SibTech, Inc.Inventors: Marina V. Backer, Joseph M. Backer
-
Patent number: 7267973Abstract: The present invention is directed to an isolated nucleic acid encoding a fusion protein comprising (1) the A subunit of Shiga-like bacterial toxin, or a truncated or mutated version thereof; and (2) human vascular endothelial growth factor, or a truncated or mutated version thereof; wherein the fusion protein possesses ribosome inactivating activity and ability to bind to cellular VEGF receptors. The present invention is also directed to polypeptides the above combination of toxin and growth factor, as well as expression vectors and transformed cells incorporating the above nucleic acid. The invention is also directed to pharmaceutical compositions and methods for treating patients suffering from diseases relating to angiogenesis.Type: GrantFiled: January 27, 2004Date of Patent: September 11, 2007Assignee: SibTech, Inc.Inventors: Marina V. Backer, Joseph M. Backer
-
Publication number: 20040166565Abstract: The present invention is directed to an isolated nucleic acid encoding a fusion protein comprising (1) the A subunit of Shiga-like bacterial toxin, or a truncated or mutated version thereof; and (2) human vascular endothelial growth factor, or a truncated or mutated version thereof; wherein the fusion protein possesses ribosome inactivating activity and ability to bind to cellular VEGF receptors. The present invention is also directed to polypeptides the above combination of toxin and growth factor, as well as expression vectors and transformed cells incorporating the above nucleic acid. The invention is also directed to pharmaceutical compositions and methods for treating patients suffering from diseases relating to angiogenesis.Type: ApplicationFiled: January 27, 2004Publication date: August 26, 2004Inventors: Marina V. Backer, Joseph M. Backer
-
Publication number: 20030059461Abstract: The present invention is directed to a molecular delivery vehicle for delivery of compounds to a target, comprising: (a) a carrier for carrying the compounds; (b) an adapter covalently linked to the carrier; and (c) a targeting protein comprising a recognition portion and a targeting portion, the recognition portion capable of binding to the adapter, the targeting portion capable of binding to the target. The present invention is also directed to pharmaceutical compositions including the above molecular delivery vehicle, and methods of delivering therapeutic, diagnostic, or research compounds to selected targets using the molecular delivery vehicle.Type: ApplicationFiled: June 1, 2001Publication date: March 27, 2003Applicant: SibTech, Inc.Inventors: Marina V. Backer, Joseph M. Backer
-
Publication number: 20010031485Abstract: The present invention is directed to an isolated nucleic acid encoding a fusion protein comprising (1) the A subunit of Shiga-like bacterial toxin, or a truncated or mutated version thereof; and (2) human vascular endothelial growth factor, or a truncated or mutated version thereof; wherein the fusion protein possesses ribosome inactivating activity and ability to bind to cellular VEGF receptors. The present invention is also directed to polypeptides the above combination of toxin and growth factor, as well as expression vectors and transformed cells incorporating the above nucleic acid. The invention is also directed to pharmaceutical compositions and methods for treating patients suffering from diseases relating to angiogenesis.Type: ApplicationFiled: March 1, 2001Publication date: October 18, 2001Applicant: SibTech, Inc.Inventors: Marina V. Backer, Joseph M. Backer
-
Patent number: 5856315Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of 7-?substituted amino!-9-?(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R.sub.2, R.sub.3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.Type: GrantFiled: May 26, 1998Date of Patent: January 5, 1999Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Peter Bohlen
-
Patent number: 5843925Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-?substituted amino!-9-?(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R.sub.2, R.sub.3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.Type: GrantFiled: December 13, 1994Date of Patent: December 1, 1998Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Peter Bohlen
-
Patent number: 5574026Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-halogen-9-[hydrogen or [(substituted glycyl)amido]]-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.Type: GrantFiled: December 13, 1994Date of Patent: November 12, 1996Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Peter Bohlen, Phaik-Eng Sum
-
Patent number: 5567693Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-(hydrogen or di (C.sub.1 -C.sub.4)alkylamino)-8-halogen-9-(substituted)-6-demethyl-6-deoxytetracycl ine of Formula I: ##STR1## wherein R, X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.Type: GrantFiled: December 13, 1994Date of Patent: October 22, 1996Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Peter Bohlen, Phaik-Eng Sum
-
Patent number: 5563130Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein W, R.sub.2 and R.sub.3 are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.Type: GrantFiled: December 13, 1994Date of Patent: October 8, 1996Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Peter Bohlen
-
Patent number: 5461029Abstract: The disclosure relates to a method of inhibiting the infectivity of a virus, the virus being characterized by the presence of a heparin-binding protein, which comprises contacting the cellular receptor for the virus or the receptor-binding protein of the virus with an effective amount of a pharmaceutical composition containing the HBNF protein, the MK protein or a combination thereof in a sufficient amount to inhibit the infectivity of the virus. Also, this disclosure concerns a method of preventing or treating a viral infection in a subject, the virus being characterized by the presence of a heparin-binding protein, which comprises administering to the subject an effective amount of a pharmaceutical composition containing HBNF, MK or a combination thereof in a sufficient amount to prevent or treat the viral infection in the subject. Further, the disclosure describes a new composition comprising a combination of the HBNF and MK proteins.Type: GrantFiled: April 24, 1992Date of Patent: October 24, 1995Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Michael R. Ostrander